IL291499B2 - Aza-quinoline compounds and uses thereof - Google Patents

Aza-quinoline compounds and uses thereof

Info

Publication number
IL291499B2
IL291499B2 IL291499A IL29149922A IL291499B2 IL 291499 B2 IL291499 B2 IL 291499B2 IL 291499 A IL291499 A IL 291499A IL 29149922 A IL29149922 A IL 29149922A IL 291499 B2 IL291499 B2 IL 291499B2
Authority
IL
Israel
Prior art keywords
amino
methyl
cyclohexyl
trans
naphthyridin
Prior art date
Application number
IL291499A
Other languages
English (en)
Hebrew (he)
Other versions
IL291499B1 (en
IL291499A (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL291499A publication Critical patent/IL291499A/en
Publication of IL291499B1 publication Critical patent/IL291499B1/en
Publication of IL291499B2 publication Critical patent/IL291499B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL291499A 2019-09-26 2020-09-24 Aza-quinoline compounds and uses thereof IL291499B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019108296 2019-09-26
PCT/CN2020/117487 WO2021057853A1 (en) 2019-09-26 2020-09-24 Aza-quinoline compounds and uses thereof

Publications (3)

Publication Number Publication Date
IL291499A IL291499A (en) 2022-05-01
IL291499B1 IL291499B1 (en) 2025-04-01
IL291499B2 true IL291499B2 (en) 2025-08-01

Family

ID=75166744

Family Applications (1)

Application Number Title Priority Date Filing Date
IL291499A IL291499B2 (en) 2019-09-26 2020-09-24 Aza-quinoline compounds and uses thereof

Country Status (11)

Country Link
US (2) US12544374B2 (cg-RX-API-DMAC7.html)
EP (1) EP4034535B1 (cg-RX-API-DMAC7.html)
JP (1) JP7763753B2 (cg-RX-API-DMAC7.html)
KR (1) KR102889562B1 (cg-RX-API-DMAC7.html)
CN (1) CN114746414B (cg-RX-API-DMAC7.html)
AU (1) AU2020355837B2 (cg-RX-API-DMAC7.html)
CA (1) CA3150284A1 (cg-RX-API-DMAC7.html)
DK (1) DK4034535T3 (cg-RX-API-DMAC7.html)
ES (1) ES3067468T3 (cg-RX-API-DMAC7.html)
IL (1) IL291499B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021057853A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4034535T3 (da) 2019-09-26 2026-04-07 Novartis Ag Aza-quinolinforbindelser og anvendelser deraf
AR123185A1 (es) * 2020-08-10 2022-11-09 Novartis Ag Compuestos y composiciones para inhibir ezh2
AR128015A1 (es) * 2021-12-16 2024-03-20 Transthera Sciences Nanjing Inc Inhibidor de cdk9 y uso del mismo
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
CN118515653B (zh) * 2024-07-23 2024-12-10 西湖制药(杭州)有限公司 一种ezh2特异性抑制剂及其制备方法和用途
CN118598873B (zh) * 2024-08-07 2024-11-19 艾斯拓康生物医药(天津)有限公司 一种手性的氮杂-喹啉类化合物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
JP2002532415A (ja) 1998-12-16 2002-10-02 ワーナー−ランバート・カンパニー Mek阻害剤による関節炎の治療
AU7349801A (en) 2000-07-19 2002-01-30 Warner Lambert Co Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
CA2478065C (en) 2002-03-08 2013-01-08 Eisai Co. Ltd. Macrocyclic compounds useful as pharmaceuticals
SG2013013339A (en) 2002-03-13 2014-12-30 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
MX2008002114A (es) 2005-07-21 2008-04-17 Ardea Biosciences Inc Inhibidores de n-(arilamino)-sulfonamida de mek.
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
WO2014155301A1 (en) 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2
MX375970B (es) 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
TW201708210A (zh) 2015-06-30 2017-03-01 葛蘭素史克智慧財產(第二)有限公司 Zeste同源物2增強子之抑制劑
JP2019524872A (ja) 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
US10689378B2 (en) 2016-06-20 2020-06-23 Novartis Ag Triazolopyridine compounds and uses thereof
MX2019004950A (es) 2016-10-28 2019-09-26 Icahn School Med Mount Sinai Composiciones y metodos para tratar el cancer mediado por el potenciador del homologo zeste 2.
DK4034535T3 (da) 2019-09-26 2026-04-07 Novartis Ag Aza-quinolinforbindelser og anvendelser deraf

Also Published As

Publication number Publication date
CN114746414B (zh) 2024-10-18
JP7763753B2 (ja) 2025-11-04
EP4034535A1 (en) 2022-08-03
CN114746414A (zh) 2022-07-12
US20260076968A1 (en) 2026-03-19
KR20220070229A (ko) 2022-05-30
US12544374B2 (en) 2026-02-10
AU2020355837B2 (en) 2025-10-02
IL291499B1 (en) 2025-04-01
WO2021057853A1 (en) 2021-04-01
KR102889562B1 (ko) 2025-11-24
AU2020355837A1 (en) 2022-02-24
DK4034535T3 (da) 2026-04-07
CA3150284A1 (en) 2021-04-01
US20220280509A1 (en) 2022-09-08
ES3067468T3 (en) 2026-05-22
JP2022550353A (ja) 2022-12-01
EP4034535B1 (en) 2026-03-04
EP4034535A4 (en) 2023-11-22
IL291499A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
IL291499B1 (en) Azaquinoline compounds and their uses
CN115803325B (zh) 一种egfr抑制剂及其制备方法和应用
KR101917972B1 (ko) ERK 억제제로서 티에노[2,3-c]피롤-4-온 유도체
CN105461695B (zh) 嘧啶或三嗪衍生物及其制备方法和用途
JP4667463B2 (ja) チロシンキナーゼ阻害剤として適する環状ジアリールウレア
AU2013300344B2 (en) N2,N4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer
JP6954567B2 (ja) 2−置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途
KR101904632B1 (ko) 2,4-이치환 페닐-1,5-디아민 유도체, 이의 응용, 및 이로 제조한 약물 조성물
JP2022550353A5 (cg-RX-API-DMAC7.html)
JP2022520448A5 (cg-RX-API-DMAC7.html)
JP6866967B2 (ja) サイクリン依存性キナーゼcdk9の新規阻害剤
JP2019163277A (ja) Egfr変異型キナーゼ活性をモジュレートするための化合物および組成物
RU2016103938A (ru) Модуляторы протеин-тирозинкиназы и способы их применения
RU2734849C2 (ru) Производные анилинпиримидина и их применения
CN111377907B (zh) 一种多取代苯氨基嘧啶衍生物及其制备方法和用途
JP2017519021A5 (cg-RX-API-DMAC7.html)
KR101846475B1 (ko) TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
CN105384694B (zh) 一种取代的氨基嘧啶衍生物及其制备方法和药物用途
JP7813282B2 (ja) ピリミジン化合物、その組成物、及びそれらの医薬用途
WO2008104754A1 (en) Novel pyrimidine derivatives 698
EP4003983A1 (en) 1,2,4-oxadiazol-5-one derivatives for the treatment of cancer
JP2023538159A5 (cg-RX-API-DMAC7.html)
JP2023522195A (ja) 炎症性疾患の治療のための置換ピリジン
JP2019537598A (ja) 2−多置換芳香族環−ピリミジン系誘導体及びその調製と医学的用途
CN112313207B (zh) 一种氰基取代吡啶及氰基取代嘧啶类化合物、制备方法及其应用